Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?

Area of Science:

• Health Economics
• Psychiatric Research
• Decision Science

Background:

• Pharmacoeconomic evaluations guide healthcare decision-making.
• Decision tree analyses model clinical and economic outcomes of medical interventions.
• Schizophrenia management requires robust economic assessment.

Purpose of the Study:

• To develop a standardized framework for economic evaluation of schizophrenia management.
• To assess the inclusion of key confounding variables in existing schizophrenia models.
• To highlight discrepancies in pharmacoeconomic analyses.

Main Methods:

• Development of a theoretical model to identify confounding variables.
• Appraisal of previously published schizophrenia economic models.
• Conducting a systematic review of schizophrenia modeling studies.
• Creation of five distinct economic models.

Main Results:

• Cost-effectiveness of atypical antipsychotics varies based on the inclusion of key confounding variables.
• Significant discrepancies exist between different analytical methods.
• Social rehabilitation influences patient outcomes and economic evaluations.

Conclusions:

• A need for standardized pharmacoeconomic models in schizophrenia management is evident.
• Standardized techniques will improve adherence to decision-maker guidelines.
• Comprehensive economic evaluations must consider factors beyond medication.